Riskpilot← Back to searchSign inGet full accessBIOSYNTH AS
ASActiveOrg 987444096Hanaveien 4-6, 4327 SandnesTechnical testing and analysis · NACE 7120Est. 20042 employees
Revenue 2024
NOK 1,8M
+57% vs 2023
EBITDA margin
-262.0%
+34% vs 2023
Equity ratio
23.9%
Financial strength
Net profit 2024
NOK -4,9M
+33% vs 2023
| Revenue | NOK 1,8M | +57% |
| EBITDA | NOK -4,7M | +34% |
| Net profit | NOK -4,9M | +33% |
| Total assets | NOK 7,8M | -24% |
| Equity | NOK 1,9M | -27% |
| Employees | 2 | — |
Legal name
BIOSYNTH AS
Org number
987444096
Legal form
Aksjeselskap
NACE code
7120 · Technical testing and analysis
Founded
9. november 2004
Share capital
NOK 113 845
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og daglig leder hver for seg.
Company purpose
Forskning, uvikling, analyse og salg av syntetiske stoffer, investere i selskaper med lignende aktiviteter og alt som dertil står i forbindelse. Selskapet skal også arbeide med utvikling og formidling av fou kompetanse og konsulentvirksomhet.
Address
Hanaveien 4-6, 4327 Sandnes
Email
sales@biosynth.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 132 | 152 | 152 | 170 | 326 | 320 | 320 | 556 | 378 | 350 | 389 | 620 | 1 524 | 631 | 421 | 1 133 | 1 777 |
| Staff expenses | −1 871 | −654 | −606 | −831 | −1 090 | −700 | −723 | −1 271 | −1 462 | −1 430 | −1 456 | −1 086 | −985 | −896 | −1 071 | −1 344 | −1 168 |
| EBITDA | −3 701 | −2 334 | −3 168 | −3 775 | −3 497 | −4 629 | −3 567 | −5 111 | −5 490 | −4 321 | −4 977 | −6 142 | −7 542 | −10 909 | −11 546 | −7 004 | −4 655 |
| Depreciation & amort. | −30 | −0 | −0 | −0 | −9 | −12 | −13 | −17 | −24 | −13 | −13 | −9 | −41 | −223 | −239 | −245 | −192 |
| EBIT | −3 731 | −2 334 | −3 168 | −3 775 | −3 506 | −4 641 | −3 580 | −5 128 | −5 514 | −4 334 | −4 990 | −6 151 | −7 583 | −11 133 | −11 785 | −7 249 | −4 847 |
| Net financials | 55 | −51 | −100 | 4 | 20 | −6 | 41 | −50 | 5 | 49 | 95 | 89 | −18 | −96 | −112 | −163 | −87 |
| Profit before tax | −3 676 | −2 385 | −3 268 | −3 771 | −3 486 | −4 647 | −3 539 | −5 177 | −5 509 | −4 285 | −4 895 | −6 062 | −7 601 | −11 228 | −11 898 | −7 412 | −4 934 |
| Tax | −0 | −0 | −0 | −5 848 | −1 193 | −1 471 | −1 204 | −1 805 | −360 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −3 676 | −2 385 | −3 268 | 2 077 | −2 293 | −3 175 | −2 335 | −3 373 | −5 149 | −4 285 | −4 895 | −6 062 | −7 601 | −11 228 | −11 898 | −7 412 | −4 934 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 537 | 2 130 | 7 060 | 11 300 | 12 526 | 13 569 | 15 839 | 24 462 | 24 007 | 16 645 | 11 449 | 5 677 | 6 582 | 16 402 | 17 095 | 10 262 | 7 814 |
| Equity | −1 116 | — | 3 592 | 8 548 | 9 855 | 12 440 | 13 358 | 23 993 | 19 922 | 15 637 | 10 743 | 4 681 | 4 580 | 3 352 | 3 454 | 2 542 | 1 865 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 757 |
| Short-term debt | 2 653 | 2 094 | 3 469 | 2 751 | 2 671 | 1 129 | 2 481 | 469 | 4 085 | 1 008 | 706 | 996 | 2 002 | 13 050 | 13 640 | 7 720 | 3 192 |
| Total debt | 2 653 | 5 267 | 3 469 | 2 751 | 2 671 | 1 129 | 2 481 | 469 | 4 085 | 1 008 | 706 | 996 | 2 002 | 13 050 | 13 640 | 7 720 | 5 949 |
EBITDA margin
-262.0%
This company
15.8%
Market median
-1758% vs market
20082024
Equity ratio
23.9%
This company
38.2%
Market median
-37% vs market
20082024
Return on equity
-264.5%
This company
18.4%
Market median
-1538% vs market
20082024
Net profit margin
-277.7%
This company
8.1%
Market median
-3528% vs market
20082024
Asset turnover
0.23×
This company
1.12×
Market median
-79% vs market
20082024
Debt / equity
3.19×
This company
0.62×
Market median
-415% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KL Chief Executive Officer | Chief Executive Officer | 2009 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Biolink Group As | Company | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Svaboe Invest As
BIOSYNTH AS Board members of BIOSYNTH AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kristian Larsen | Chief Executive Officer | 0 companies |
| Kåre Svaboe | Board of Directors | 0 companies |
| Sjur Svaboe | Chairman | 0 companies |